文献速递临床试验与 GCP流行病学与生物统计

多剂次口服昂丹司琼治疗儿童胃肠炎:DOSE-AGE实用随机对照试验方案

Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial.
PubMed 文献 · Trials · 2020-05-27

针对急诊就诊后呕吐的急性胃肠炎患儿,临床常带药回家多剂次使用昂丹司琼,但缺乏证据。DOSE-AGE为随机、安慰剂对照、双盲、六中心实用试验,计划纳入1030名6月龄至18岁儿童,比较48小时按需口服昂丹司琼溶液与安慰剂,主要结局为7天内中重度胃肠炎(改良Vesikari量表)。

要点

  • 急诊已用一剂昂丹司琼的胃肠炎患儿,随机接受48小时按需口服昂丹司琼或安慰剂。
  • 主要结局为7天内改良Vesikari量表评估的中重度胃肠炎。
  • 同时评估呕吐腹泻持续时间、非计划就诊、静脉补液、照护者满意度及安全性。

核心结论

  • 目前缺乏确定性数据指导急诊后多剂次昂丹司琼的临床使用,该实用试验旨在评估其效果与安全性。

研究设计与样本

  • 随机、安慰剂对照、双盲、六中心实用临床试验,在加拿大六个儿童急诊科开展。
  • 2019年9月开始招募6月龄至18岁、入组前24小时至少呕吐3次、胃肠炎症状<72小时且急诊已用一剂昂丹司琼的儿童。
  • 计划招募1030名儿童,按1:1通过互联网第三方随机化服务分配。
  • 干预为48小时供应(即六剂)昂丹司琼口服溶液或安慰剂,按需服用。
  • 参与者、照护者及结局评估者均对分组设盲,入组后24、48和168小时通过照护者问卷收集结局数据。

关键数值与推荐

  • 主要结局为急诊就诊后7天内发生中重度胃肠炎,采用经验证的改良Vesikari量表测量。
  • 次要结局包括呕吐和腹泻的持续时间与频率、非计划就诊和静脉补液的比例、照护者治疗满意度及安全性。
  • 计划在试验同期开展预先设计的经济学评价。

临床怎么用

  • 该试验结果将为急诊后是否常规给予多剂次昂丹司琼提供证据,当前 expanding practice 缺乏支持证据且带来未量化的成本和资源使用影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited treatment options that clinicians can provide to children presenting to emergency departments with vomiting secondary to acute gastroenteritis. Based on evidence of effectiveness and safety, clinicians now routinely administer ondansetron in the emergency department to promote oral rehydration therapy success. However, clinicians are also increasingly providing multiple doses of ondansetron for home use, creating unquantified cost and health system resource use implications without any evidence to support this expanding practice. METHODS/DESIGN: DOSE-AGE is a randomized, placebo-controlled, double-blinded, six-center, pragmatic clinical trial being conducted in six Canadian pediatric emergency departments (EDs). In September 2019 the study began recruiting children aged 6 months to 18 years with a minimum of three episodes of vomiting in the 24 h preceding enrollment, <72 h of gastroenteritis symptoms and who were administered a dose of ondansetron during their ED visit. We are recruiting 1030 children (1:1 allocation via an internet-based, third-party, randomization service) to receive a 48-h supply (i.e., six doses) of ondansetron oral solution or placebo, administered on an as-needed basis. All participants, caregivers and outcome assessors will be blinded to group assignment. Outcome data will be collected by surveys administered to caregivers 24, 48 and 168 h following enrollment. The primary outcome is the development of moderate-to-severe gastroenteritis in the 7 days following the ED visit as measured by a validated clinical score (the Modified Vesikari Scale). Secondary outcomes include duration and frequency of vomiting and diarrhea, proportions of children experiencing unscheduled health care visits and intravenous rehydration, caregiver satisfaction with treatment and safety. A preplanned economic evaluation will be conducted alongside the trial. DISCUSSION: Definitive data are lacking to guide the clinical use of post-ED visit multidose ondansetron in children with acute gastroenteritis. Usage is increasing, despite the absence of supportive evidence. The incumbent additional costs associated with use, and potential side effects such as diarrhea and repeat visits, create an urgent need to evaluate the effect and safety of multiple doses of ondansetron in children focusing on post-emergency department visit and patient-centered outcomes. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03851835. Registered on 22 February 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Freedman SB, Williamson-Urquhart S, Heath A, et al. Multi-dose Oral Ondansetron for Pediatric Gastroenteritis: study Protocol for the multi-DOSE oral ondansetron for pediatric Acute GastroEnteritis (DOSE-AGE) pragmatic randomized controlled trial. Trials. 2020. PMID: 32460879. doi:10.1186/s13063-020-04347-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。